SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABSW
SAB Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.60+0.07 (+2.77%)
Close on Oct 19, 2026
- Market cap
- $207.36M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.09 (+3.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
SAB Biotherapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$45.71M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$71.82M
TTM Q2 2026
Free cash flow
-$45.71M
FY2025
EPS, diluted
-$0.79
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $207.36M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.97
- Dividend yield
- –
- Free cash flow yield
- -22.04%
Fundamentals
- Revenue
- $0
- Net income
- -$12.78M
- EPS, diluted
- -$0.79
- Free cash flow
- -$45.71M
- Book value per share
- $2.69
- Diluted shares
- 80M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$71.82M
Net income
-$12.78M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months